Citius Pharmaceuticals Inc (CTXR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Citius Pharmaceuticals Inc (CTXR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8163
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Mino-Lok, an antibiotic lock solution intended for the treatment of patients with catheter-related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine intended to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. Citius is headquartered in Cranford, New Jersey, the US.

Citius Pharmaceuticals Inc (CTXR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Leonard-Meron Biosciences Raises USD0.6 Million in Venture Financing 12
Licensing Agreements 13
Leonard Meron Biosciences Expands Licensing Agreement with Novel Anti-Infective Therapeutics 13
Leonard-Meron Biosciences Amends Licensing Agreement with Novel Anti-Infective Therapeutics 14
Equity Offering 15
Citius Pharma Raises USD10 Million in Public Offering of Shares and Warrants 15
Citius Pharma Plans to Raise USD5.6 Million in Public Offering of Shares 17
Citius Pharma to Raise USD2 Million in Private Placement of Shares 18
Citius Pharma Plans to Raise Funds through Public Offering of Shares 19
Citius Pharma to Raise USD6 Million in Private Placement of Shares 20
Citius Pharma Plans to Raise up to USD50 Million in Public Offering of Shares and Warrants 21
Citius Pharma Raises USD6.8 Million in Public Offering of Shares and Warrants 22
Citius Pharma Raises USD0.8 Million in Third Tranche of Private Placement of Units 24
Citius Pharma Raises USD0.2 Million in Seconds Tranche of Private Placement of Units 25
Citius Pharma Plans to Raise Funds in Public Offering of Shares 26
Citius Pharma Raises USD0.4 Million in Private Placement of Units 27
Citius Pharma Raises USD4.6 Million in Private Placement of Units 28
Citius Pharma Raises USD3 Million in Private Placement of Shares 29
Citius Pharma Raises USD1.5 Million in Private Placement of Units 30
Citius Pharma Raises USD0.1 Million in Private Placement of Units 31
Citius Pharma Raises USD2.04 Million in Private Placement of Shares 32
Acquisition 33
Citius Pharma Acquires Leonard Meron Biosciences 33
Trail One Acquires Citius Pharma in Reverse Takeover Transaction 34
Citius Pharmaceuticals Inc – Key Competitors 35
Citius Pharmaceuticals Inc – Key Employees 36
Citius Pharmaceuticals Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Product News 38
02/13/2018: Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias 38
Clinical Trials 39
Mar 06, 2018: Citius Reports Progress in Hemorroid Treatment Program 39
Feb 15, 2018: Citius Announces Enrollment Of First Patient In The Mino-Lok Phase 3 Trial 40
Dec 06, 2017: Mino-Lok Phase 3 Clinical Trial Supplies Shipped to Sites 41
Nov 07, 2017: International Study at MD Anderson Sister Institutions Supports Mino Lok Phase 2b Results: Poster Presented at ID Week 42
Oct 31, 2017: Citius Pharmaceuticals Receives “Fast Track” Designation By FDA For Mino-Lok Investigational Trial 43
Sep 05, 2017: Citius Pharmaceuticals Provides Phase 3 Update On Mino-Lok Clinical Trial Following FDA Meeting 44
Jan 11, 2017: Citius Mino-Lok Addresses Resistant Pathogens 45
Other Significant Developments 46
Oct 11, 2017: Citius Pharmaceuticals Issues Shareholder Letter 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Citius Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Leonard-Meron Biosciences Raises USD0.6 Million in Venture Financing 12
Leonard Meron Biosciences Expands Licensing Agreement with Novel Anti-Infective Therapeutics 13
Leonard-Meron Biosciences Amends Licensing Agreement with Novel Anti-Infective Therapeutics 14
Citius Pharma Raises USD10 Million in Public Offering of Shares and Warrants 15
Citius Pharma Plans to Raise USD5.6 Million in Public Offering of Shares 17
Citius Pharma to Raise USD2 Million in Private Placement of Shares 18
Citius Pharma Plans to Raise Funds through Public Offering of Shares 19
Citius Pharma to Raise USD6 Million in Private Placement of Shares 20
Citius Pharma Plans to Raise up to USD50 Million in Public Offering of Shares and Warrants 21
Citius Pharma Raises USD6.8 Million in Public Offering of Shares and Warrants 22
Citius Pharma Raises USD0.8 Million in Third Tranche of Private Placement of Units 24
Citius Pharma Raises USD0.2 Million in Seconds Tranche of Private Placement of Units 25
Citius Pharma Plans to Raise Funds in Public Offering of Shares 26
Citius Pharma Raises USD0.4 Million in Private Placement of Units 27
Citius Pharma Raises USD4.6 Million in Private Placement of Units 28
Citius Pharma Raises USD3 Million in Private Placement of Shares 29
Citius Pharma Raises USD1.5 Million in Private Placement of Units 30
Citius Pharma Raises USD0.1 Million in Private Placement of Units 31
Citius Pharma Raises USD2.04 Million in Private Placement of Shares 32
Citius Pharma Acquires Leonard Meron Biosciences 33
Trail One Acquires Citius Pharma in Reverse Takeover Transaction 34
Citius Pharmaceuticals Inc, Key Competitors 35
Citius Pharmaceuticals Inc, Key Employees 36
Citius Pharmaceuticals Inc, Subsidiaries 37

List of Figures
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Citius Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Citius Pharmaceuticals Inc (CTXR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Orbotech Ltd.:企業の戦略的SWOT分析
    Orbotech Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Waterstone Financial Inc (WSBF):企業の財務・戦略的SWOT分析
    Waterstone Financial Inc (WSBF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • NV Energy Inc:企業の戦略的SWOT分析
    NV Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Idexx Laboratories Inc (IDXX):企業の財務・戦略的SWOT分析
    Idexx Laboratories Inc (IDXX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Verbund AG (VER):企業の財務・戦略的SWOT分析
    Verbund AG (VER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Immune Pharmaceuticals Inc (IMNP):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designe …
  • Halt Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Halt Medical Inc (Halt Medical) is a healthcare service center that develops, manufactures and commercializes medical treatment for women with symptomatic uterine fibroids. The center offers Acessa System, a minimally invasive laparoscopic outpatient procedure to treat uterine fibroids. It o …
  • Sandoz Inc:企業のM&A・事業提携・投資動向
    Sandoz Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sandoz Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Addario Lung Cancer Medical Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Addario Lung Cancer Medical Institute (ALCMI) is a non-profit organization that concentrates on scientific and clinical research and diagnostics for lung cancer. The organization involves in research advancements, invests in discovery of improved treatments and also facilitates early detecti …
  • Reata Pharmaceuticals Inc (RETA):企業の財務・戦略的SWOT分析
    Summary Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription fa …
  • ConverGene LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary ConverGene LLC (ConverGene) is a small molecule discovery company that offers development of cancer drugs targeting the root regulatory mechanisms within cancer cells. The company develops small-molecule drugs that aim at bromodomains, a structural feature of proteins, which mediate epigenet …
  • Guangshen Railway Company Limited:企業の戦略・SWOT・財務情報
    Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report Summary Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • 220 Laboratories Inc.:企業の戦略・SWOT・財務情報
    220 Laboratories Inc. - Strategy, SWOT and Corporate Finance Report Summary 220 Laboratories Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Schiller AG:企業の戦略的SWOT分析
    Schiller AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Miragen Therapeutics Inc (MGEN):企業の財務・戦略的SWOT分析
    Miragen Therapeutics Inc (MGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Vascular Concepts Ltd:企業の製品パイプライン分析2018
    Summary Vascular Concepts Ltd (Vascular Concepts) formerly known as Medical Concepts Ltd is a medical device company that designs, develops and manufactures endovascular medical devices for the treatment of arterial diseases. Its products include coronary stents, peripheral stents and balloon. Vascu …
  • Tractor Supply Co:戦略・SWOT・企業財務分析
    Tractor Supply Co - Strategy, SWOT and Corporate Finance Report Summary Tractor Supply Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • G4S plc:企業の戦略・SWOT・財務分析
    G4S plc - Strategy, SWOT and Corporate Finance Report Summary G4S plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Fulcrum Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company that focuses on the discovery and development of small molecule therapies to unlock the gene regulation in disease. The company’s pipeline products include Fragile X syndrome, Facioscapulohumeral muscular dystrophy …
  • Mari Petroleum Co Ltd (MARI):石油・ガス:M&Aディール及び事業提携情報
    Summary Mari Petroleum Co Ltd (MPCL) is an integrated exploration and production company. It carries out exploration and production of crude oil, natural gas, condensate and liquefied petroleum gas (LPG). The company operates through exploration and production assets across four provinces in Pakista …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆